Search Close


Interim Results for the six month period to 31 October 2009

29th January 2010

Scancell (SCLP.PL), the developer of therapeutic cancer and infectious disease vaccines based on its
patented ImmunoBody® platform, is pleased to announce the interim results for the six month period ended 31st October 2009 (‘the period’).


  • Licensing agreement signed with Merck KGaA for two key patents required for further development and commercialisation of protein ImmunoBody® vaccines
  • Agreement signed with Ichor Medical Systems to use Ichor's TriGrid™ electroporation device for the delivery of SCIB1
  • Signed a research agreement with ImmunoVaccine Technologies Inc. to explore IVT’s DepoVax™ delivery system for future use with Scancell’s ImmunoBody® DNA infectious disease and animal health vaccines

Post Period Highlights:

  • GMP production of SCIB1 vaccine completed successfully with excellent yield
  • PharmaNet Development Group appointed to conduct and manage the SCIB1 clinical trial

David Evans, Non-Executive Chairman of Scancell, commented:

“The Company is on track with its clinical programme as outlined in our admission document in 2008, and we look forward to further progress during the current year, as SCIB1 enters Phase I clinical trials.”

A copy of this announcement is available for download at Announcement

The interim financial information is not audited.

For further information contact:

Professor Lindy Durrant  -  Scancell Holdings Plc  -     +44 (0)207 245 1100

Kirsty Corcoran/  -         Hansard Communications  -  +44 (0)207 245 1100
John Bick                                                                    +44 (0)7515 588 947

Ross Andrews  -  Zeus Capital  -                                +44 (0)161 831 1512

View the full results 

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00